

## Special Issue

# SARS-CoV-2 Variants: Unraveling Vaccines and Immune Responses

### Message from the Guest Editor

This Special Issue explores the relationship between SARS-CoV-2 variants, vaccine development, and the immune system. We encourage submissions on genomic, molecular, and structural features of SARS-CoV-2 variants and their implications for vaccine effectiveness. We also seek studies on immune response dynamics in the context of these variants. Potential topics of interest include, but are not limited to:

1. Comprehensive characterization of emerging SARS-CoV-2 variants and their unique features; 2. Evaluation of the effectiveness of currently available vaccines against variant strains; 3. Analysis of the immune response elicited by vaccines targeting SARS-CoV-2 variants; 4. Investigation of variant-specific immune evasion mechanisms and their impact on breakthrough infections; 5. Long-term durability and persistence of vaccine-induced immunity against variant strains; 6. Assessment of alternative vaccination strategies or booster doses to address variant challenges; 7. Understanding the implications of SARS-CoV-2 variants on global vaccination efforts and public health interventions; 8. Real-world effectiveness studies of vaccines against variant strains in diverse populations.

### Guest Editor

Dr. Zijun Wang

Laboratory of Molecular Immunology, The Rockefeller University, New York City, NY, USA

### Deadline for manuscript submissions

closed (31 March 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/176211](https://mdpi.com/si/176211)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).